Unpacking the Potential of HER3-Targeted Therapy in NSCLC
In this podcast, Helena Yu, MD, and Rebecca S. Heist, MD, MPH, discuss ongoing clinical trials of HER3-targeted therapy for patients with advanced NSCLC and how these agents have the potential to change treatment options in this setting.
Decera Clinical Education Oncology Podcast · Helena Yu MD, Rebecca S. Heist MD MPH
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
This second episode in a 3-part series on HER3-targeted agents in NSCLC covers current clinical trials with HER3-targeted therapy, including:
- Recent data on patritumab deruxtecan (HER3-DXd) in the HERTHENA-Lung01 trial
- The EGFRxHER3 bispecific antibodies BL-B01D1 and izalontamab
- The HER2xHER3 bispecific antibody zenocutuzumab
- The HER3-targeted antibody–drug conjugate SHR-A2009
Presenters in this series include:
Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts
Helena Yu, MD
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Supported by an educational grant from Daiichi Sankyo, Inc.
Link to full program, including a downloadable highlights slideset:
https://bit.ly/48ecElW
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.